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Introduction 
Mining large drug-oriented knowledge graphs enables 
predicting Adverse Drug Reactions (ADRs) [1, 2]. Indeed, 
these graphs encompass knowledge elements about the 
molecular mechanism of drugs (e.g. drug targets, Gene 
Ontology annotations, gene variations, pathways). However, 
only few works [3] explored further these graphs in the search 
for mechanistic explanation for this type of events. We assume 
that features documenting molecular mechanisms that take 
part in the prediction are particularly interesting features, since 
they may provide novel knowledge for the mechanism that 
may be underlying an ADR. We propose to explore PGxLOD 
[4], a knowledge graph built around drugs and 
pharmacogenomic processes in which they are involved, 
through the lens of several ADR datasets, each focusing on a 
particular type of ADRs. Particularly, we propose to use 
features resulting from the exploration of PGxLOD in a 
prediction task where best predictive features will be 
considered as potential elements of explanation. 
Methods 
Following reference studies, we distinguish drugs associated 
with three families of ADRs: (1) Human Leukocyte Antigen 
system related ADR, (n=104); (2) Drug Induced Liver Injury 
(n=1036); (3) Severe Cutaneous Adverse Reactions (n=874). 
In each case, we add a set of negative drugs, i.e., drugs most 
probably not associated with an ADR of the family in 
question, with distinct methods. Regarding (1), positive drugs 
are supposed to be associated with type B effects 
(idiosyncratic), then we selected a set of drugs associated with 
type A effects (dose-related) to define negative examples. 
Negative drugs associated with (2) and (3) were provided by 
reference studies, but were cleaned by litterature review. 
Drugs from the resulting list are then mapped to those defined 
in PGxLOD, to enable exploring the graph for features 
describing each drug. Various graph exploration methods are 
tested in parallel to generate various sets of features. First, all 
nodes in a neighbourhood of 5 hops from a drug are 
considered. Second, we select only nodes more connected to  
positive drugs than to negative and inversely, using a 
threshold ratio. Third, we use neighbouring nodes, paths to 
them and their ontology classes to build a feature matrix.  
Results 
After setting negative examples and mapping with PGxLOD, 
drug lists (1) (2) and (3) are respectively composed of 
55/452/106 positive and 747/268/334 negative drugs. Results 
in regards with graph exploration, feature selection and 
evaluation are ongoing at the time we write this abstract. 
Discussion & Conclusion 
We hypothesize that PGxLOD encompasses an original set of 
features potentially intangible in the databases it is connecting. 
We will present how their iterative heuristical selection permit 
to identify candidate features to potentially explain ADRs. 
Groups of ADRs from Side Effect Resource (SIDER) and 
expert reviewing will be employed to evaluate our method. 
We initiated this work during the BioHackathon 2018 Paris 
(https://bh2018paris.info), and are actively pursuing. 
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